Beta
Back to 4167.TW Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
revenue-chart

4167 Revenue

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

default symbol

4167

松瑞藥

18.95D

-0.79%

(-0.01)

松瑞藥 (4167.TW) 2025Q4 financial report shows revenue of 319.87M TWD, with a YoY growth rate of 15.50%. This data clearly demonstrates significant revenue growth, with the company showing strong operational momentum and a marked increase in market demand. To fully capture future growth potential and investment opportunities, investors should closely monitor 松瑞藥 (4167.TW)’s upcoming financial reports and key strategic adjustments, and leverage diversified data analysis, especially advanced tools like Growin AI Value Analysis, for a comprehensive and forward-looking evaluation.